Approval, reimbursement and pricing of high-cost cancer medicines in Australia
نویسنده
چکیده
Background Australian government expenditures on chemotherapy medicines are increasing faster than any other area of health care with an average annual growth rate of 63% from 2009/10 to 2013/14. Funding decisions on new, high-cost cancer medicines are challenging because of insufficient evidence on benefits and risks of new cancer medicines and high prices requested by pharmaceutical companies. We reviewed the current approval, reimbursement and pricing strategies for cancer medicines and the development of new regulatory and funding pathways in Australia.
منابع مشابه
Registration and Reimbursement of New Cancer Medicines in Australia.
I read with interest the article by Macaulay et al. [1] in a recent issue of Value in Health Regional Issues for Asia on the registration and reimbursement of certain medicines for patients with cancer in Australia. This topic is of considerable public interest in Australia given the current Senate inquiry on timely access to new medicines for patients with cancer on the Pharmaceutical Benefits...
متن کاملEvidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.
OBJECTIVE To review the use of evidence in the market approval process, reimbursement, and price control mechanisms for medicines and medical devices in Thailand, South Korea, and Taiwan. METHODS Documentary reviews supplemented by interviews with senior policymakers of relevant public health authorities. RESULTS Drug regulatory authorities play a vital role in the market authorization proc...
متن کاملDilemmas in the compassionate supply of investigational cancer drugs.
In Australia, patients who want to access medicines that are not yet approved have only two options: to enroll in a clinical trial if they are eligible, or obtain their medicine through 'compassionate supply', which is provided at the discretion of the manufacturer. In this article, we explore ethical issues associated with the provision of oncology medicines that are still in development, eith...
متن کاملPolicy options to deal with high-cost medicines – survey with European policy-makers
Background The affordability and financing of new, frequently high-cost, medicines pose challenges to governments world-wide. In Europe, the continual introduction of new premium-priced medicines is of special concern and requires adapted policy options. The aim of the study was to survey whether and which pricing and reimbursement policy options European countries have implemented for new prem...
متن کاملRegistration and Reimbursement of New Cancer Medicines in Australia-Response to Letter to the Editor by Michael Wonder.
We welcome the comments on our article on the regulatory and reimbursement approval of oncology drugs in Australia lacking any supportive phase 3 data [1]. The author of the letter raises a series of discussion points, and a detailed response addressing each of these can be found in the following paragraphs. We believe that the arguments do not detract from the central tenets of our article, wh...
متن کامل